Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2016-07-26Clinical Trial Update: Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL [Phase 2]
A Phase 2 clinical trial update evaluating an abbreviated Rituximab-CHOP regimen in completely excised stage I/II diffuse large B-cell lymph…
-
CLINICAL_TRIALS research · 2016-07-25Clinical Trial Update: R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis [Phase 3]
Phase 3 trial comparing Rituximab-containing dose-adjusted EPOCH-21 versus a Rituximab-containing mNHL-BFM-90 program with Autologous Stem C…
-
CLINICAL_TRIALS research · 2016-07-01Clinical Trial Update: Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
This entry notes a terminated observational study at Stanford evaluating the RCHOP chemotherapy regimen with or without radiation therapy fo…
-
CLINICAL_TRIALS research · 2016-06-17Clinical Trial Update: Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update investigates low-dose radiotherapy for diffuse large B-cell lymphoma. The current status is UNKNOWN.
-
CLINICAL_TRIALS research · 2016-06-09Clinical Trial Update: Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over [Phase 2]
Phase II trial evaluating the addition of rituximab to a reduced-dose CHOP regimen in elderly patients with diffuse large B-cell lymphoma; c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-06-07Clinical Trial Update: Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
Phase 2 trial of an epigenetic modulation approach in relapsed/refractory Diffuse Large B-Cell Lymphoma was terminated; results were posted …
-
CLINICAL_TRIALS research · 2016-06-06Clinical Trial Update: CNS Prophylaxis in Diffuse Large B-cell Lymphoma [Phase 3]
Update on a Phase 3 trial evaluating CNS prophylaxis in diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 [Phase 3]
This update reports the completion of a multicentre, randomized Phase III trial evaluating rituximab as maintenance therapy versus observati…
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse [Phase 1, Phase 2]
This completed Phase Ib/II trial evaluated the efficacy and safety of the R-CMC544/R-GEMOX combination in patients with diffuse large B-cell…
-
CLINICAL_TRIALS trial_result · 2016-05-16Clinical Trial Update: A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients [Phase 3]
Phase 3 clinical trial comparing S-CHOP to R-CHOP in untreated CD20-positive diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS other · 2016-05-04Clinical Trial Update: CyBeR Association in Relapsed/Refractory DLBCL [Phase 2]
Phase 2 clinical trial update on the CyBeR association for relapsed/refractory diffuse large B-cell lymphoma, with current status listed as …
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating bendamustine with subcutaneous rituximab in patients with diffuse large B-cell lymphoma; the study …
-
CLINICAL_TRIALS trial_result · 2016-04-25Clinical Trial Update: A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease [Phase 1]
Phase 1 trial results for obinutuzumab in Chinese participants with CD20+ malignant disease. Diseases studied include chronic lymphocytic le…
-
CLINICAL_TRIALS trial_result · 2016-04-19Clinical Trial Update: Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma h…
-
CLINICAL_TRIALS trial_result · 2016-04-18Clinical Trial Update: Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
This completed study analyzes prognostic factors (clinical and biological) in patients with refractory or relapsed diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2016-04-15Clinical Trial Update: A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib [Phase 3]
Phase 3 clinical trial updating the evaluation of molecular-guided therapy for diffuse large B-cell lymphoma with Bortezomib has completed.
-
CLINICAL_TRIALS trial_result · 2016-04-11Clinical Trial Update: Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide with or without rituximab after standard chemotherapy in patients with diffuse large B-cell lymphoma; …
-
CLINICAL_TRIALS trial_result · 2016-03-23Clinical Trial Update: Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
Phase 2 study evaluating the anti-CD20 antibody ofatumumab in combination with ICE chemotherapy for diffuse large B-cell lymphoma has comple…
-
CLINICAL_TRIALS withdrawal · 2016-03-16Clinical Trial Update: Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating RICE followed by GARD for relapsed or refractory diffuse large B-cell lymphoma was withdrawn, with no re…
-
EMA safety_alert · 2016-03-11EMA reviews cancer medicine Zydelig
The EMA reviews the cancer medicine Zydelig (idelalisib) for potential safety concerns and evaluates available data.
-
CLINICAL_TRIALS withdrawal · 2016-03-03Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating rituximab in combination with chemotherapy for untreated high- or high-intermediate-risk diffuse large B-cell lym…
-
CLINICAL_TRIALS withdrawal · 2016-02-23Clinical Trial Update: R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL [Phase 3]
Phase 3 trial comparing R-CHOP alone versus R-CHOP with radiotherapy for localized CD20+ Diffuse Large B-Cell Lymphoma was withdrawn (sponso…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
This ClinicalTrials.gov entry notes completion and posting of results for a trial evaluating rituximab in combination with CHOP or CHOP-like…
-
CLINICAL_TRIALS trial_result · 2016-02-15Clinical Trial Update: Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom [Phase 2]
A Phase 2 study evaluating transplantation using Zevalin (ibritumomab tiuxetan) with BEAM conditioning in patients with refractory diffuse l…
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma [Phase 3]
Phase 3 study comparing subcutaneous versus intravenous rituximab added to CHOP in previously untreated CD20-positive diffuse large B-cell l…